Response to Carboplatin and Paclitaxel in the treatment of hereditary breast ovarian cancer syndrome (HBOC): a case report

被引：0

作者：

Mehmood, Faisal ^{[1
]}

Touseef, Mumtaz ^{[2
]}

Ashraf, Amna ^{[2
]}

Rai, Izza Ali ^{[3
]}

机构：

[1] Combined Mil Hosp, Dept Radiol, Lahore, Pakistan

[2] Combined Mil Hosp, Dept Med, Lahore, Pakistan

[3] Combined Mil Hosp, Dept Vasc Surg, Lahore, Pakistan

来源：

JOURNAL OF THE PAKISTAN MEDICAL ASSOCIATION | 2024年 / 74卷 / 12期

关键词：

Hereditary breast ovarian cancer; Breast cancer; Ovarian cancer; HBOC; BRCA; PALB2; Chemotherapy; Carboplatin; Paclitaxel; PREVALENCE; MUTATIONS;

D O I：

10.47391/JPMA.20059

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The co-occurrence of primary breast cancer and primary ovarian cancer is an exceptional hereditary phenomenon and results from inherent mutations in critical genes like a unique case of hereditary breast-ovarian cancer syndrome (HBOC) reported in Combined Military Hospital, Lahore, Pakistan. It was marked by pathogenic variants in RAD51D, PALB2, CHEK1, and TP53 genes. Remarkably, the patient exhibited an outstanding response to the chemotherapy agents, Carboplatin and Paclitaxel. This dynamic treatment not only led to nearly complete remission of high-grade ovarian serous cancer but also triggered regression in grade-2 invasive ductal breast cancer after just a few rounds of chemotherapy. Consequently, what started as palliative care evolved into a curative triumph.

引用

页码：2184 / 2187

页数：4

共 50 条

[31] Hereditary Breast and Ovarian Cancer Syndrome and Issues in Pediatric and Adolescent Practice
Herman, Jonathan D.
Appelbaum, Heather
JOURNAL OF PEDIATRIC AND ADOLESCENT GYNECOLOGY, 2010, 23 (04) : 253 - 258
[32] Paclitaxel (Taxol(R)) plus carboplatin as first-line treatment for advanced ovarian cancer
Ozols, RF
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 1996, 6 : 9 - 12
[33] Usefulness of desensitization protocol for a carboplatin hypersensitivity reaction during docetaxel-carboplatin therapy for recurrent ovarian cancer: Case report
Shoji, Tadahiro
Takatori, Eriko
Kaido, Yoshitaka
Kumagai, Seisuke
Takeuchi, Satoshi
Yoshizaki, Akira
Sugiyama, Toru
ONCOLOGY LETTERS, 2010, 1 (06) : 1021 - 1023
[34] The "Leuven" dose-dense paclitaxel/carboplatin regimen in patients with recurrent ovarian cancer
Cadron, Isabelle
Leunen, Karin
Amant, Frederic
Van Gorp, Toon
Neven, Patrick
Vergote, Ignace
GYNECOLOGIC ONCOLOGY, 2007, 106 (02) : 354 - 361
[35] Nilotinib in Combination with Carboplatin and Paclitaxel Is a Candidate for Ovarian Cancer Treatment
Weigel, Marion T.
Rath, Katrin
Alkatout, Ibrahim
Wenners, Antonia S.
Schem, Christian
Maass, Nicolai
Jonat, Walter
Mundhenke, Christoph
ONCOLOGY, 2014, 87 (04) : 232 - 245
[36] Evaluation of combined bevacizumab and intraperitoneal carboplatin or paclitaxel therapy in a mouse model of ovarian cancer
Shah, Dhaval K.
Veith, Jean
Bernacki, Ralph J.
Balthasar, Joseph P.
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 68 (04) : 951 - 958
[37] Secondary leukemia after treatment with paclitaxel and carboplatin in a patient with recurrent ovarian cancer
See, HT
Thomas, DA
Bueso-Ramos, C
Kavanagh, J
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2006, 16 : 236 - 240
[38] Paclitaxel and Carboplatin Treatment for Advanced Ovarian Cancer during Pregnancy
Ramos, Jesus Ruiz
Roma, Eva
Palomar, Laura
Poveda, Jose Luis
CHEMOTHERAPY, 2013, 59 (05) : 344 - 345
[39] Georgia Primary Care Providers' Knowledge of Hereditary Breast and Ovarian Cancer Syndrome
Nair, Navya
Bellcross, Cecelia
Haddad, Lisa
Martin, Monique
Matthews, Roland
Gabram-Mendola, Sheryl
Crane, Barbara
Meaney-Delman, Dana
JOURNAL OF CANCER EDUCATION, 2017, 32 (01) : 119 - 124
[40] Results of reinduction therapy with paclitaxel and carboplatin in recurrent epithelial ovarian cancer
Gronlund, B
Hogdall, C
Hansen, HH
Engelholm, SA
GYNECOLOGIC ONCOLOGY, 2001, 83 (01) : 128 - 134

← 1 2 3 4 5 →